Twoja Przychodnia SCM

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis7 trials
• Crohn's disease4 trials
• Obesity2 trials
• Atopic dermatitis (eczema)1 trial
• Irritable bowel syndrome1 trial

Phase

• Phase 35 trials
• Phase 24 trials
• Phase 2/32 trials

Status

• Recruiting8 trials
• Terminated2 trials
• Completed1 trial

Lead sponsor

• Eli Lilly and Company7 trials
• Bristol-Myers Squibb1 trial
• InDex Pharmaceuticals1 trial
• Pfizer1 trial
• Shire1 trial

Running trials

• Recruiting

  A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

  NCT07545759· Phase 2· Eli Lilly and Company· Source

  Contact: Beata Gawdis-Wojnarska (principal investigator)

• Recruiting

  A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

  NCT07483099· Phase 2· Eli Lilly and Company· Source

  Contact: Beata Gawdis-Wojnarska (principal investigator)

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Eli Lilly and Company· Source

  Contact: Beata Gawdis-Wojnarska (principal investigator)

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Eli Lilly and Company· Source

  Contact: Beata Gawdis-Wojnarska (principal investigator)

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

  Contact: Beata Gawdis-Wojnarska (principal investigator)

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

  Contact: Beata Gawdis-Wojnarska (principal investigator)

• Recruiting

  A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

  NCT05076175· Phase 2/3· Bristol-Myers Squibb· Source

  Contact: Beata Gawdis-Wojnarska, Site 0088

• Recruiting

  A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

  NCT04844606· Phase 3· Eli Lilly and Company· Source

  Contact: Beata Gawdis-Wojnarska (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ulcerative colitis5 recruiting
• Crohn's disease3 recruiting
• Obesity2 recruiting
• Irritable bowel syndrome1 recruiting

Closed trials

• Terminated

  A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

  NCT05732454· Phase 2/3· Pfizer· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· InDex Pharmaceuticals· Source

• Completed

  A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085· Phase 3· Shire· Source